Breast Cancer: Medical Treatments
The question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of recognising lobular breast cancer as a distinct disease in the NICE Treatment Guidelines.
Answered by Preet Kaur Gill
The National Institute for Health and Care Excellence (NICE) is not currently producing guidance specifically on lobular breast cancer. Patients with invasive lobular breast cancer can access NICE-recommended targeted treatments on the same basis as other breast cancer patients, where they meet the clinical criteria in NICE’s guidance.
In 2023, NICE considered updating its breast cancer guidelines and received feedback that invasive lobular breast cancer may require separate recommendations. However, no systematic review evidence specific to this condition was identified. NICE maintains surveillance of new evidence that may affect its published guidance and decisions on whether its guidance should be updated are taken through an established prioritisation process.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →